dc.contributor.author | Lavie, David | |
dc.contributor.author | Timmerman, John | |
dc.contributor.author | Garcia-Sanz, Ramon | |
dc.contributor.author | Kim, Won Seog | |
dc.contributor.author | Kim, Tae Min | |
dc.contributor.author | Avigdor, Abraham | |
dc.contributor.author | Dierickx, Daan | |
dc.contributor.author | Jagadeesh, Deepa | |
dc.contributor.author | Molin, Daniel L. | |
dc.contributor.author | Herrera, Alex F. | |
dc.date.accessioned | 2024-03-12T10:26:29Z | |
dc.date.available | 2024-03-12T10:26:29Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Lavie, D., Timmerman, J., Garcia-Sanz, R., Kim, W. S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008. 65th Annual Meeting of the American-Society-of-Hematology (ASH). San Diego, CA, 09-12 December, 2023. https://dx.doi.org/10.1182/blood-2023-182119 | en_US |
dc.identifier.issn | 0006-4971 | |
dc.identifier.issn | 1528-0020 | |
dc.identifier.uri | https://dx.doi.org/10.1182/blood-2023-182119 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12357 | |
dc.description.abstract | Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. However, most patients eventually develop progressive disease and optimal therapy after anti-PD-1 failure has not been determined. The inhibitory checkpoint receptor, lymphocyte-activation gene 3 (LAG-3) is expressed in cHL tumor microenvironments and upregulation of LAG-3 is considered to play an important role in anti-PD-1 resistance. Favezelimab (MK-4280) is a humanized immunoglobulin G4 antibody that binds to LAG-3 and blocks interaction with major histocompatibility complex Class II ligands. Results from the ongoing phase 1/2 MK-4280-003 study of the combination of favezelimab and pembrolizumab demonstrated manageable safety and promising antitumor activity in patients with anti-PD-1-refractory R/R cHL. The randomized, open-label, parallel group, active-controlled, phase 3 KEYFORM-008 study (NCT05508867) is designed to evaluate efficacy and safety of the coformulation of favezelimab and pembrolizumab versus physician's choice of chemotherapy in patients with anti-PD-1-refractory R/R cHL. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | American Society of Hematology | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Randomized | en_US |
dc.subject | Coformulated Favezelimab | en_US |
dc.subject | Anti-PD-1 Therapy | en_US |
dc.title | Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008 | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | 65th Annual Meeting of the American-Society-of-Hematology (ASH) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 142 | en_US |
dc.identifier.issue | 1 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1182/blood-2023-182119 | en_US |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001159740302191 | en_US |